Citi tells investors it s time to sell Moderna after 600%

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-30T12:12:09.479Z • Permanent link

Citi's analysts have sent shockwaves through the biotech sector by advising investors to sell Moderna stock, citing that the company's revenue and profit forecasts fail to justify the 600% surge in its share price. The analyst report, dated September 25, 2023, highlights concerns over the sustainability of Moderna's growth prospects and the increasing competition in the mRNA vaccine space.

According to Citi, the main driver behind Moderna's stock price hike has been the company's impressive clinical trial results and partnerships with major pharmaceutical companies. However, the analysts argue that these achievements do not translate to long-term financial performance. Specifically, they point out that Moderna's average selling price for its COVID-19 vaccine is around $800, which is significantly lower than the prices commanded by similar vaccines in other countries, such as the UK and Japan. Furthermore, the analysts question whether Moderna's mRNA technology can be scaled up efficiently and cost-effectively, a crucial factor in the long-term viability of its business model.

Citi's analysts also express concerns over Moderna's regulatory hurdles, particularly in the US market. The company's vaccine has already faced scrutiny over its efficacy and safety profile, and the analysts worry that future regulatory challenges could impact Moderna's ability to expand its product pipeline. Furthermore, Citi notes that the company's reliance on government contracts and grants may limit its ability to generate consistent revenue streams in the future.

Moderna's stock price collapse has significant implications for the biotech sector as a whole. The company's stock price has been a bellwether for the industry, and its decline could lead to a broader sell-off in biotech stocks. Furthermore, the Citi report could have a ripple effect on the research communities and academia, as investors and analysts may become more cautious in their assessments of other biotech companies. Specifically, the report may lead to increased scrutiny of companies like Pfizer and BioNTech, which have also benefited from the mRNA vaccine hype.

Moreover, the Citi report highlights the need for investors to take a more nuanced view of Moderna's business prospects. While the company's achievements in the COVID-19 vaccine space are undeniably impressive, they do not necessarily translate to long-term financial success. As a result, investors should be more cautious in their assessments of Moderna's growth prospects and consider a more diversified portfolio of biotech stocks.

The Citi report is the latest in a series of analyst assessments that have questioned the sustainability of the mRNA vaccine hype. In recent months, several other analysts have expressed similar concerns, citing issues with the high costs of mRNA production, the need for continued government funding, and the challenges of scaling up production. Furthermore, the report is part of a broader trend in the biotech sector, as investors and analysts become increasingly cautious in their assessments of companies that have benefited from the COVID-19 vaccine boom.